Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
Open Access
- 25 June 2020
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 136, 4-6
- https://doi.org/10.1016/j.ejca.2020.06.017
Abstract
No abstract availableKeywords
Funding Information
- Genentech
- Merck
- BMS
- Affimed
- Adaptive
- Roche
- Tensha
- IGM
This publication has 19 references indexed in Scilit:
- Vaccines for the prevention against the threat of MERS-CoVExpert Review of Vaccines, 2016
- The effect of rituximab on vaccine responses in patients with immune thrombocytopeniaBlood, 2013
- Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximabEuropean Journal of Neurology, 2013
- Rituximab-Treated Patients Have a Poor Response to Influenza VaccinationJournal of Clinical Immunology, 2012
- Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatmentBlood, 2011
- Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin’s Lymphoma Patients Treated with Rituximab-Containing RegimensThe Journal of Immunology, 2011
- Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trialArthritis & Rheumatism, 2009
- Attenuated Antibody Reaction for the Primary Antigen but not for the Recall Antigen of Influenza Vaccination in Patients with Non-Hodgkin B-Cell Lymphoma after the Administration of Rituximab-CHOPJournal of Clinical and Experimental Hematopathology, 2009
- Rituximab treatment results in impaired secondary humoral immune responsivenessBlood, 2002
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998